Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAOR.L Regulatory News (AOR)

  • There is currently no data for AOR

Medical Advisory Board

15 Aug 2006 07:00

Aortech International PLC15 August 2006 15 August 2006 AorTech International plc ("AorTech" or "the Company") AorTech International plc appoints Medical Advisory Board Key opinion leaders in breast plastic surgery come on board London, UK - AorTech International plc (AIM: AOR), the medical devicedevelopment and biomaterials intellectual property and licensing company, todayannounces the creation of a Medical Advisory Board, with the appointment ofesteemed plastic surgeons, V. Leroy Young, M.D., and Mark L Jewell, M.D. Betweenthem, they bring eighty years' combined experience in plastic surgery. TheMedical Advisory Board will play a key role in the development and promotion ofAorTech's unique and highly versatile Elast-EonTM product, in a range ofsurgical applications. Leroy Young (aged 60) is currently Plastic Surgeon and Partner at Body AestheticPlastic Surgery & Skincare Centre, Chief of Surgical Services, Barnes-JewishWest County Hospital and a Consultant at the Breast Implant Research Group atWashington University, St Louis, Missouri. Over a period of 13 years he played akey leadership role in the American Society for Aesthetic Plastic Surgeons(ASAPS), where he served on the Board of Directors and held a number ofcommittee positions, including leadership in strategic planning, finance andinvestment and patient safety issues. Dr Young is on the Breast Implant TaskForce, and a key opinion leader and publisher of articles (over 170) in thisfield. Mark Jewell (aged 58) is an Assistant Clinical Professor of Plastic Surgery atOregon Health Science University in Portland, Oregon and has practiced plasticsurgery in Eugene, Oregon for the last 27 years. He holds several leadershippositions at the ASAPS and is currently Immediate Past President. He is alsoCo-Chair of the Breast Implant Task Force and Group Co-Chair of the BreastImplant Work Group for the ASAPS and ASPS (American Society of PlasticSurgeons). Mark also brings valuable experience in general and breast surgery tothe Medical Advisory Board. He has extensive experience of technologicalinnovations in plastic surgery in plastic surgery and has authored 40peer-reviewed articles and books. With these two appointments, AorTech will have access to regulatory, strategicand practical advice, as well as a high level of counsel from these key opinionleaders. Frank Maguire, Chief Executive of AorTech, said: "The appointment of Drs. Jewell and Young, who are both highly regarded surgeonsand researchers, adds great credence to AorTech's proposition. The aim is thatthey will guide, advise and challenge the current AorTech team and provide avaluable sounding board for the Group. "A key strand to our development programme over the coming months will be topursue proof of concept for the minimally invasive breast implant, at which timewe will seek a partner to take this product through clinical trials andultimately to commercial use. With the Medical Advisory Board in place, webelieve we are well positioned to pursue our goals and take full advantages ofthe opportunity that we believe will emerge with the continued evolution andregulatory advances within this market place." -Ends-Enquiries: AorTech International plc Tel: +1 801 581 0854Frank Maguire, Chief Executive Officer Hogarth Partnership Limited Tel: +44 (0)20 7357 9477Melanie Toyne-Sewell / Andrew Jaques/Sarah Richardson This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Sep 20067:03 amRNSAGM Statement
19th Sep 20064:47 pmRNSHolding(s) in Company
15th Sep 20065:09 pmRNSDirector/PDMR Shareholding
13th Sep 20061:32 pmRNSHolding(s) in Company
13th Sep 20061:31 pmRNSHolding(s) in Company
6th Sep 200612:13 pmRNSAnnual Report and Accounts
5th Sep 20067:03 amRNSDirector/PDMR Shareholding
5th Sep 20067:02 amRNSHolding(s) in Company
31st Aug 20067:01 amRNSFinal Results
15th Aug 20067:00 amRNSMedical Advisory Board
7th Aug 20067:02 amRNSFirst human use of ElastEon
1st Aug 20062:20 pmRNSHolding(s) in Company
19th Jul 20067:01 amRNSHolding(s) in Company
30th Jun 200612:20 pmRNSDirector/PDMR Shareholding
23rd Jun 200611:01 amRNSHolding(s) in Company
28th Apr 20063:38 pmRNSConference Presentation
13th Apr 200611:36 amRNSChange of Adviser
6th Apr 20064:06 pmRNSNotification of Interests
20th Mar 20067:01 amRNSSupply and License Agreement
24th Jan 20068:54 amRNSAward of Govt Grant Funding
9th Dec 20057:01 amRNSInterim Results
7th Dec 20057:01 amRNSUpdate of Postal Poll
25th Nov 20057:00 amRNSFDA Approval
17th Nov 20057:01 amRNSAGM Update
15th Nov 20052:25 pmRNSDirectorate Change
27th Oct 20051:06 pmRNSAGM Statement
23rd Sep 20057:01 amRNSFinal Results
1st Aug 20057:01 amRNSSpinal Disc Licence
13th May 20057:00 amRNSBoard Changes
29th Apr 20057:00 amRNSBreast Implants Presentations

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.